Synopsis
Synopsis
0
EU WC
0
KDMF
0
VMF
DRUG PRODUCT COMPOSITIONS0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 5 Fluorouracil
2. 5 Fluorouracil Biosyn
3. 5 Fu Lederle
4. 5 Fu Medac
5. 5 Hu Hexal
6. 5-fluorouracil
7. 5-fluorouracil-biosyn
8. 5-fu
9. 5-fu Lederle
10. 5-fu Medac
11. 5-hu Hexal
12. 5fu
13. Adrucil
14. Carac
15. Dakota, Fluorouracile
16. Efudex
17. Efudix
18. Fluoro Uracile Icn
19. Fluoro-uracile Icn
20. Fluoroplex
21. Fluorouracil Gry
22. Fluorouracil Mononitrate
23. Fluorouracil Monopotassium Salt
24. Fluorouracil Monosodium Salt
25. Fluorouracil Potassium Salt
26. Fluorouracil-gry
27. Fluorouracile Dakota
28. Fluorouracilo Ferrer Far
29. Fluoruracil
30. Fluracedyl
31. Flurodex
32. Haemato Fu
33. Haemato-fu
34. Neofluor
35. Onkofluor
36. Ribofluor
1. 5-fluorouracil
2. 51-21-8
3. 5-fu
4. Fluoroplex
5. Efudex
6. Adrucil
7. Carac
8. 5-fluoropyrimidine-2,4(1h,3h)-dione
9. Fluracil
10. Fluoroblastin
11. Queroplex
12. Kecimeton
13. Phthoruracil
14. Carzonal
15. Timazin
16. Arumel
17. Efudix
18. Fluril
19. 5-fluoracil
20. Fluracilum
21. Ulup
22. 5-fluoro-1h-pyrimidine-2,4-dione
23. Fluorouracilum
24. Fluro Uracil
25. 5 Fluorouracil
26. 5-fluoruracil
27. Ftoruracil
28. Efurix
29. Fluri
30. 5-fluoro-2,4(1h,3h)-pyrimidinedione
31. 5-fluoropyrimidine-2,4-dione
32. Effluderm (free Base)
33. Fluorouracilo
34. 2,4(1h,3h)-pyrimidinedione, 5-fluoro-
35. 2,4-dihydroxy-5-fluoropyrimidine
36. Ro 2-9757
37. Uracil, 5-fluoro-
38. 5-fluoropyrimidine-2,4-diol
39. 5-fluor-2,4-pyrimidindiol
40. 5-fluoro Uracil
41. 5-fluoro-uracil
42. 5-ftouracyl
43. 2,4-dioxo-5-fluoropyrimidine
44. Nsc 19893
45. Nsc-19893
46. Fluorouracil, 5-
47. 5-fluoro-2,4-pyrimidinedione
48. Fluorouracil (adrucil)
49. Fluorouricil
50. Ro-2-9757
51. Tolak
52. 5-fluor-2,4-dihydroxypyrimidin
53. U-8953
54. 191047-65-1
55. Fu
56. Chembl185
57. 2,4-pyrimidinediol, 5-fluoro- (9ci)
58. Mls000069498
59. 5 Fu
60. 5fu
61. Fluroblastin
62. Phtoruracil
63. Chebi:46345
64. Fluoro-uracile
65. Fluoro-uracilo
66. U3p01618rt
67. Nsc19893
68. 5-fluoro-1,2,3,4-tetrahydropyrimidine-2,4-dione
69. 5-faracil
70. Cinco Fu
71. Ro-29757
72. 191047-64-0
73. 191115-88-5
74. Urf
75. Ncgc00015442-02
76. Fluorouracile
77. Effluderm
78. Smr000038082
79. Dsstox_cid_634
80. Fluorouracile [dcit]
81. 5-fluoracil [german]
82. 5-fluoracyl
83. 5-fluoruracil [german]
84. Dsstox_rid_75705
85. Dsstox_gsid_20634
86. Fluorouracilum [inn-latin]
87. Fluorouracilo [inn-spanish]
88. 5-fluoropyrimidin-2,4-diol
89. Fluorouracil Cream
90. Cas-51-21-8
91. Fluoroplex (tn)
92. 5-fluor-2,4-pyrimidindiol [czech]
93. Adrucil (tn)
94. Ccris 2582
95. Carac (tn)
96. 5-fluor-2,4-dihydroxypyrimidin [czech]
97. Hsdb 3228
98. Sr-01000075881
99. 5-fluor-2,4(1h,3h)-pyrimidindion [czech]
100. Einecs 200-085-6
101. 5-fluor-2,4(1h,3h)-pyrimidindion
102. Fluouracil
103. Inhibits Thymilidate Synthetase
104. Unii-u3p01618rt
105. 2,4-dioxo-5-fluoropryimidine
106. 5-fluorourasil
107. Ai3-25297
108. Fluoro Uracil
109. 5-florouracil
110. 5-fluorouacil
111. 5-fu (tn)
112. 5-fluracil
113. 1upf
114. 5f-uracil
115. U 8953
116. 1-fluoro-1h-pyrimidine-2,4-dione
117. Adrucil (icn)
118. Mfcd00006018
119. Adrucil (fluorouracil)
120. Fluorouracil - Adrucil
121. Fluorouracil [usan:usp:inn:ban:jan]
122. Spectrum_000841
123. Opera_id_134
124. 5-fluorouracil, 99%
125. Spectrum2_000076
126. Spectrum3_000434
127. Spectrum4_000557
128. Spectrum5_000718
129. Wln: T6mvmvj Ef
130. Fluorouracil [mi]
131. Lopac-f-6627
132. F0151
133. Fluorouracil [inn]
134. Fluorouracil [jan]
135. Upcmld-dp130
136. Ec 200-085-6
137. F 6627
138. Fluorouracil [hsdb]
139. Fluorouracil [usan]
140. Schembl3646
141. 5-fluorpyrimidin-2,4-diol
142. Fluorouracil [vandf]
143. Lopac0_000536
144. Bspbio_002048
145. Fluorouracil [mart.]
146. Kbiogr_001253
147. Kbioss_001321
148. 2(1h)-pyrimidinone, 5-fluoro-4-hydroxy- (9ci)
149. 4(3h)-pyrimidinone, 5-fluoro-2-hydroxy- (9ci)
150. Mls002415705
151. Divk1c_000054
152. Fluorouracil [usp-rs]
153. Fluorouracil [who-dd]
154. Fluorouracil [who-ip]
155. Spectrum1500305
156. Spbio_000291
157. 5-fluorouracil [iarc]
158. 5-fluoro-2,4-dioxo-pyrimidin
159. 5-fluoro-pyrimidine-2,4-diol
160. Gtpl4789
161. Dtxsid2020634
162. Upcmld-dp130:001
163. Fluorouracil (jp17/usp/inn)
164. Hms500c16
165. Kbio1_000054
166. Kbio2_001321
167. Kbio2_003889
168. Kbio2_006457
169. Kbio3_001268
170. 5-fluoro-2,3h)-pyrimidinedione
171. 5-fluorouracil [who-ip]
172. 2,4-pyrimidinedione, 5-fluoro-
173. Ninds_000054
174. Bcpp000428
175. Fluorouracil [orange Book]
176. Hms1920o18
177. Hms2090i04
178. Hms2091f19
179. Hms3259o03
180. Hms3261l13
181. Hms3654k22
182. Hms3715h03
183. Hms3865l03
184. Pharmakon1600-01500305
185. Fluorouracil [ep Monograph]
186. 5-fluorouracil, Analytical Standard
187. Bcp02083
188. 2,3h)-pyrimidinedione, 5-fluoro-
189. Fluorouracil (5-fluoracil, 5-fu)
190. Fluorouracil (5-fluoracil; 5-fu)
191. Fluorouracil [usp Monograph]
192. Tox21_110150
193. Tox21_202335
194. Tox21_300112
195. Tox21_500536
196. Bdbm50340677
197. Ccg-39879
198. Dl-399
199. Nsc757036
200. Nsc816997
201. S1209
202. Stk297802
203. Stl367375
204. Zinc38212689
205. Fluorouracilum [who-ip Latin]
206. Akos000119162
207. Akos003237897
208. Akos008044307
209. Tox21_110150_1
210. Bcp9000239
211. Cs-0993
212. Db00544
213. Ks-5129
214. Lp00536
215. Nc00454
216. Nsc-757036
217. Nsc-816997
218. Sdccgsbi-0050519.p005
219. Flucytosine Impurity A [who-ip]
220. Idi1_000054
221. Ncgc00015442-01
222. Ncgc00015442-03
223. Ncgc00015442-04
224. Ncgc00015442-05
225. Ncgc00015442-06
226. Ncgc00015442-07
227. Ncgc00015442-08
228. Ncgc00015442-09
229. Ncgc00015442-10
230. Ncgc00015442-11
231. Ncgc00015442-12
232. Ncgc00015442-15
233. Ncgc00015442-16
234. Ncgc00015442-24
235. Ncgc00015442-30
236. Ncgc00091349-01
237. Ncgc00091349-02
238. Ncgc00091349-03
239. Ncgc00091349-04
240. Ncgc00091349-05
241. Ncgc00091349-07
242. Ncgc00091349-08
243. Ncgc00254023-01
244. Ncgc00259884-01
245. Ncgc00261221-01
246. 1004-03-1
247. 5-fluoro-2,4-(1h,3h)-pyrimidinedione
248. Ac-11201
249. Bf166014
250. Emtricitabine Impurity F [who-ip]
251. Hy-90006
252. Nci60_001652
253. Sri-10792-04
254. Sri-10792-05
255. Sri-10792-06
256. Sri-10792_07
257. Sri-10792_08
258. 5-fluoro-1h-pyrimidine-2,4-dione(5fu)
259. 5-fluorouracil, >=99% (hplc), Powder
260. Sbi-0050519.p004
261. 5-fluoro-1h-pyrimidine-2,4-dione(5-fu)
262. Db-051923
263. Db-065735
264. 5-fluoro-1h-pyrimidine-2,4-dione (5-fu)
265. Am20100252
266. Eu-0100536
267. Flucytosine Impurity A [ep Impurity]
268. Ft-0601511
269. Ft-0668745
270. Ft-0695666
271. Ft-0695667
272. Ft-0707652
273. Sw199617-3
274. 5-fluoro-1h-pyrimidine-2,4-dione(5-fura)
275. Fluorouracil, Meets Usp Testing Specifications
276. 51f218
277. C07649
278. D00584
279. 5-fluorouracil, Vetec(tm) Reagent Grade, >=99%
280. Q238512
281. W-60379
282. (5-fluorouracil)5-fluoro-1h-pyrimidine-2,4-dione
283. 5-fluoro-1h-pyrimidine-2,4-dione(5-fluoro Uracil)
284. Sr-01000075881-1
285. Sr-01000075881-3
286. Sr-01000075881-5
287. W-202929
288. 5-fluoro-1h-pyrimidine-2,4-dione (5-fluorouracil)
289. Brd-k24844714-001-02-1
290. 5-fluoropyrimidin-2,4(1h,3h)-dione [who-ip]
291. Z275128052
292. 5-fluoro-1h-pyrimidine-2,4-dione(5-fluorouracil)(5-fu)
293. 5-fluorouracil, Certified Reference Material, Tracecert(r)
294. Fluorouracil, British Pharmacopoeia (bp) Reference Standard
295. Fluorouracil, European Pharmacopoeia (ep) Reference Standard
296. Fluorouracil, United States Pharmacopeia (usp) Reference Standard
297. Pyrimidine Antimetabolite: Inhibits Nucleic Acid Replication; Tetratogen
298. Fluorouracil, Pharmaceutical Secondary Standard; Certified Reference Material
| Molecular Weight | 130.08 g/mol |
|---|---|
| Molecular Formula | C4H3FN2O2 |
| XLogP3 | -0.9 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 0 |
| Exact Mass | 130.01785550 g/mol |
| Monoisotopic Mass | 130.01785550 g/mol |
| Topological Polar Surface Area | 58.2 Ų |
| Heavy Atom Count | 9 |
| Formal Charge | 0 |
| Complexity | 199 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 8 | |
|---|---|
| Drug Name | Carac |
| PubMed Health | Fluorouracil |
| Drug Classes | Antineoplastic Agent, Antineoplastic, Dermatological |
| Drug Label | Carac (fluorouracil cream) Cream, 0.5%, contains fluorouracil for topical dermatologic use. Chemically, fluorouracil is 5-fluoro-2,4(1H, 3H)-pyrimidinedione. The molecular formula is C4H3FN2O2. Fluorouracil has a molecular weight of 130.08.Carac Cr... |
| Active Ingredient | Fluorouracil |
| Dosage Form | Cream |
| Route | Topical |
| Strength | 0.5% |
| Market Status | Prescription |
| Company | Valeant Bermuda |
| 2 of 8 | |
|---|---|
| Drug Name | Efudex |
| PubMed Health | Fluorouracil |
| Drug Classes | Antineoplastic Agent, Antineoplastic, Dermatological |
| Drug Label | Efudex Solutions and Cream are topical preparations containing the fluorinated pyrimidine 5-fluorouracil, an antineoplastic antimetabolite.Efudex Solution consists of 2% or 5% fluorouracil on a weight/weight basis, compounded with propylene glycol, t... |
| Active Ingredient | Fluorouracil |
| Dosage Form | Cream; Solution |
| Route | Topical |
| Strength | 5%; 2% |
| Market Status | Prescription |
| Company | Valeant Pharm Intl |
| 3 of 8 | |
|---|---|
| Drug Name | Fluoroplex |
| PubMed Health | Fluorouracil |
| Drug Classes | Antineoplastic Agent, Antineoplastic, Dermatological |
| Drug Label | FLUOROPLEX (fluorouracil) 1% Topical Cream is an antineoplastic/antimetabolite product for dermatological use. Fluorouracil has the empirical formula C4H3FN2O2 and a molecular weight of 130.08. It is sparingly soluble in water and slightly soluble... |
| Active Ingredient | Fluorouracil |
| Dosage Form | Cream |
| Route | Topical |
| Strength | 1% |
| Market Status | Prescription |
| Company | Aqua Pharms |
| 4 of 8 | |
|---|---|
| Drug Name | Fluorouracil |
| Drug Label | Fluorouracil Injection, USP an antineoplastic antimetabolite, is a sterile, nonpyrogenic injectable solution for intravenous administration. Each mL contains 50 mg of fluorouracil and water for injection. Sodium hydroxide may be added to adjust pH to... |
| Active Ingredient | Fluorouracil |
| Dosage Form | Cream; Injectable; Solution |
| Route | Injection; Topical |
| Strength | 5gm/100ml (50mg/ml); 1gm/20ml (50mg/ml); 500mg/10ml (50mg/ml); 5%; 2%; 2.5gm/50ml (50mg/ml) |
| Market Status | Prescription |
| Company | Accord Hlthcare; Spear Pharms; Teva Pharms Usa; Taro; Sandoz; Fresenius Kabi Usa; Ebewe Pharma; Onco Therapies |
| 5 of 8 | |
|---|---|
| Drug Name | Carac |
| PubMed Health | Fluorouracil |
| Drug Classes | Antineoplastic Agent, Antineoplastic, Dermatological |
| Drug Label | Carac (fluorouracil cream) Cream, 0.5%, contains fluorouracil for topical dermatologic use. Chemically, fluorouracil is 5-fluoro-2,4(1H, 3H)-pyrimidinedione. The molecular formula is C4H3FN2O2. Fluorouracil has a molecular weight of 130.08.Carac Cr... |
| Active Ingredient | Fluorouracil |
| Dosage Form | Cream |
| Route | Topical |
| Strength | 0.5% |
| Market Status | Prescription |
| Company | Valeant Bermuda |
| 6 of 8 | |
|---|---|
| Drug Name | Efudex |
| PubMed Health | Fluorouracil |
| Drug Classes | Antineoplastic Agent, Antineoplastic, Dermatological |
| Drug Label | Efudex Solutions and Cream are topical preparations containing the fluorinated pyrimidine 5-fluorouracil, an antineoplastic antimetabolite.Efudex Solution consists of 2% or 5% fluorouracil on a weight/weight basis, compounded with propylene glycol, t... |
| Active Ingredient | Fluorouracil |
| Dosage Form | Cream; Solution |
| Route | Topical |
| Strength | 5%; 2% |
| Market Status | Prescription |
| Company | Valeant Pharm Intl |
| 7 of 8 | |
|---|---|
| Drug Name | Fluoroplex |
| PubMed Health | Fluorouracil |
| Drug Classes | Antineoplastic Agent, Antineoplastic, Dermatological |
| Drug Label | FLUOROPLEX (fluorouracil) 1% Topical Cream is an antineoplastic/antimetabolite product for dermatological use. Fluorouracil has the empirical formula C4H3FN2O2 and a molecular weight of 130.08. It is sparingly soluble in water and slightly soluble... |
| Active Ingredient | Fluorouracil |
| Dosage Form | Cream |
| Route | Topical |
| Strength | 1% |
| Market Status | Prescription |
| Company | Aqua Pharms |
| 8 of 8 | |
|---|---|
| Drug Name | Fluorouracil |
| Drug Label | Fluorouracil Injection, USP an antineoplastic antimetabolite, is a sterile, nonpyrogenic injectable solution for intravenous administration. Each mL contains 50 mg of fluorouracil and water for injection. Sodium hydroxide may be added to adjust pH to... |
| Active Ingredient | Fluorouracil |
| Dosage Form | Cream; Injectable; Solution |
| Route | Injection; Topical |
| Strength | 5gm/100ml (50mg/ml); 1gm/20ml (50mg/ml); 500mg/10ml (50mg/ml); 5%; 2%; 2.5gm/50ml (50mg/ml) |
| Market Status | Prescription |
| Company | Accord Hlthcare; Spear Pharms; Teva Pharms Usa; Taro; Sandoz; Fresenius Kabi Usa; Ebewe Pharma; Onco Therapies |
Antimetabolites; Antimetabolites, Antineoplastic; Immunosuppressive Agents
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
Fluorouracil is indicated for palliative treatment of carcinoma of the colon, rectum, breast, stomach, and pancreas in patients considered to be incurable by surgery or other means. /Included in US product update/
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2007., p. 1430
Fluorouracil is also indicated for treatment of bladder carcinoma, prostatic carcinoma, epithelial ovarian carcinoma, cervical carcinoma, endometrial carcinoma, anal carcinoma, esophageal carcinoma,metastatic tumors of skin carcinoma, and hepatoblastoma, and is used by intra-arterial injection for treatment of hepatic tumors and head and neck tumors. /Not included in US product label/
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2007., p. 1430
Fluorouracil, in combination therapy, is reasonable medical therapy at some point in the management of adrenocortical carcinoma, vulvar carcinoma, penile carcinoma and carcinoid tumors (gastrointestinal and neuroendocrine tumors). /Not included in US product label/
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2007., p. 1430
For more Therapeutic Uses (Complete) data for FLUOROURACIL (12 total), please visit the HSDB record page.
Anorexia and nausea are common adverse effects of fluorouracil, and vomiting occurs frequently. These reactions generally occur during the first week of therapy, can often be alleviated by antiemetics, and generally subside within 2 or 3 days following therapy. Stomatitis is one of the most common and often the earliest sign of specific toxicity, appearing as early as the fourth day but more commonly on the fifth to eighth day of therapy. Diarrhea, which also occurs frequently, usually appears slightly later than stomatitis, but may occur concurrently or even in the absence of stomatitis. Esophagitis, proctitis, and GI ulceration and bleeding have been reported, and paralytic ileus occurred in two patients who received excessive dosage. Patients must be closely monitored for adverse GI effects.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2007., p. 1046
Leukopenia, predominantly of the granulocytopenic type, thrombocytopenia, and anemia occur commonly with fluorouracil therapy; leukopenia usually occurs after an adequate course of fluorouracil therapy. Pancytopenia and agranulocytosis also have occurred. The patient's hematologic status must be carefully monitored. The nadir of the white blood cell count usually occurs from the ninth to the fourteenth day after therapy is initiated but may occur as late as the 25th day after the first dose of fluorouracil. Maximum thrombocytopenia has been reported to occur from the seventh to seventeenth day of therapy. Hematopoietic recovery is usually rapid and by the thirtieth day, blood cell counts have usually reached the normal range.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2007., p. 1047
Hair loss occurs frequently with fluorouracil therapy, and cosmetically significant alopecia has occurred in a substantial number of patients. Regrowth of hair has been reported even in patients receiving repeated courses of the drug. Partial loss of nails has occurred rarely, and diffuse melanosis of the nails has been reported. The most common type of dermatologic toxicity is a pruritic maculopapular rash which usually appears on the extremities and less frequently on the trunk. This rash is generally reversible and usually responsive to symptomatic treatment.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2007., p. 1047
An erythematous, desquamative rash involving the hands and feet has been reported in patients receiving fluorouracil (in some cases, prolonged infusions of high dosages of the drug were administered). The rash may be accompanied by tingling or painful hands and feet, swollen palms and soles, and phalangeal tenderness. These adverse effects, referred to as palmar-plantar erythrodysesthesia or hand-foot syndrome, may gradually disappear over 5-7 days after discontinuance of fluorouracil therapy.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2007., p. 1047
For more Drug Warnings (Complete) data for FLUOROURACIL (31 total), please visit the HSDB record page.
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
FDA Label
Fluorouracil is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances from becoming incorporated into DNA during the "S" phase (of the cell cycle), stopping normal development and division. Fluorouracil blocks an enzyme which converts the cytosine nucleotide into the deoxy derivative. In addition, DNA synthesis is further inhibited because Fluorouracil blocks the incorporation of the thymidine nucleotide into the DNA strand.
Antimetabolites, Antineoplastic
Antimetabolites that are useful in cancer chemotherapy. (See all compounds classified as Antimetabolites, Antineoplastic.)
Immunosuppressive Agents
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)
Antimetabolites
Drugs that are chemically similar to naturally occurring metabolites, but differ enough to interfere with normal metabolic pathways. (From AMA Drug Evaluations Annual, 1994, p2033) (See all compounds classified as Antimetabolites.)
L01BC02
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agents
L01B - Antimetabolites
L01BC - Pyrimidine analogues
L01BC02 - Fluorouracil
Absorption
28-100%
Route of Elimination
Seven percent to 20% of the parent drug is excreted unchanged in the urine in 6 hours; of this over 90% is excreted in the first hour. The remaining percentage of the administered dose is metabolized, primarily in the liver.
Given by continuous iv infusion for 24 hr, plasma concn in range of 0.5 to 3.0 uM are obtained and urinary excretion of fluorouracil is only 4%.
Gilman, A.G., T.W. Rall, A.S. Nies and P. Taylor (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York, NY. Pergamon Press, 1990., p. 1229
Fluorouracil readily enters cerebrospinal fluid, and concn of about 7 uM are reached within 30 min after iv admin; values are sustained for approx 3 hr and subside slowly during period of 9 hr.
Gilman, A.G., T.W. Rall, A.S. Nies and P. Taylor (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York, NY. Pergamon Press, 1990., p. 1229
Fluorouracil crosses the placenta in rats.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2007., p. 1048
Following iv administration of fluorouracil, no intact drug is detected in plasma after 3 hours.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2007., p. 1048
For more Absorption, Distribution and Excretion (Complete) data for FLUOROURACIL (7 total), please visit the HSDB record page.
Hepatic. The catabolic metabolism of fluorouracil results in degradation products ( e.g., CO2, urea and -fluoro--alanine) which are inactive.
A small portion of fluorouracil is anabolized in the tissues to 5-fluoro-2'-deoxyuridine and then to 5-fluoro-2'-deoxyuridine-5'-monophosphate, the active metabolite of the drug. The major portion of the drug is degraded in the liver. The metabolites are excreted as respiratory carbon dioxide and as urea, alpha-fluoro-beta-alanine, alpha-fluoro-beta-guanidopropionic acid, and alpha-fluoro-beta-ureidopropionic acid in urine. Following a single iv dose of fluorouracil, approximately 15% of the dose is excreted in urine as intact drug within 6 hours; over 90% of this is excreted in the first hour.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2007., p. 1048
... Dihydropyrimidine dehydrogenase /is/ an NADPH-requiring homodimeric protein (Mr ~210 kDa) containing FMN/FAD, and an iron-sulfur cluster in each subunit. The enzyme is located mainly in liver cytosol, where it catalyzes the reduction of 5-fluorouracil and related pyrimidines ...
Klaassen, C.D. (ed). Casarett and Doull's Toxicology. The Basic Science of Poisons. 6th ed. New York, NY: McGraw-Hill, 2001., p. 149
... Several routes are available for the formation of the 5'-monophosphate nucleotide (F-UMP) in animal cells. 5-FU may be converted to fluorouridine by uridine phosphorylase and then to F-UMP by uridine kinase, or it may react directly with 5-phosphoribosyl-1-pyrophosphate (PRPP), in a reaction catalyzed by ... orotate phosphoribosyl transferase, to form F-UMP. Many metabolic pathways are available to F-UMP, including incorporation into RNA. A reaction sequence crucial for antineoplastic activity involves reduction of the diphosphate nucleotide by the enzyme ribonucleoside diphosphate reductase to the deoxynucleotide level and the eventual formation of 5-fluoro-2'-deoxyuridine-5'-phosphate (F-dUMP). 5-FU also may be converted directly to the deoxyriboside 5-FUdR by the enzyme thymidine phosphorylase and further to F-dUMP, a potent inhibitor of thymidylate synthesis, by thymidine kinase ... The folate cofactor, 5,10-methylenetetrahydrofolate, and F-dUMP form a covalently bound ternary complex with the enzyme /thymidylate synthase/ ...
Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill, 2001., p. 1405
... Metabolic degradation /of 5-FU and floxuridine/ occurs in many tissues, particularly in liver. Floxuridine is converted by thymidine or deoxyuridine phosphorylases into 5-FU. 5-FU is inactivated by reduction of the pyrimidine ring; this reaction is carried out by dihydropyrimidine dehydrogenase (DPD), which is found in liver, intestinal mucosa, tumor cells, and other tissues ... Its metabolite, 5-fluoro-5,6-dihydrouracil ... is ultimately degraded to alpha-fluoro-beta-alanine ... Although the liver contains high concn of DPD, dosage does not have to be modified in patients with hepatic dysfunction, presumably because of degradation of the drug at extrahepatic sites or by vast excess of this enzyme in the liver ...
Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill, 2001., p. 1407
5-Fluorouracil is a known human metabolite of Tegafur.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
10-20 minutes
Following iv administration, the plasma elimination half-life averages about 16 minutes (range: 8-20 minutes) and is dose dependent.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2007., p. 1048
Rapid iv admin of 5-FU produces plasma concn of 0.1 to 1.0 mM; plasma clearance is rapid (half-life 10 to 20 min) ...
Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill, 2001., p. 1407
The precise mechanism of action has not been fully determined, but the main mechanism of fluorouracil is thought to be the binding of the deoxyribonucleotide of the drug (FdUMP) and the folate cofactor, N510-methylenetetrahydrofolate, to thymidylate synthase (TS) to form a covalently bound ternary complex. This results in the inhibition of the formation of thymidylate from uracil, which leads to the inhibition of DNA and RNA synthesis and cell death. Fluorouracil can also be incorporated into RNA in place of uridine triphosphate (UTP), producing a fraudulent RNA and interfering with RNA processing and protein synthesis.
5-FU requires enzymatic conversion to the nucleotide (ribosylation and phosphorylation) in order to exert its cytotoxic activity. Several routes are available for the formation of the 5'-monophosphate nucleotide (F-UMP) in animal cells. 5-FU may be converted to fluorouridine by uridine phosphorylase and then to F-UMP by uridine kinase, or it may react directly with 5-phosphoribosyl-1-pyrophosphate (PRPP), in a reaction catalyzed by ... orotate phosphoribosyl transferase, to form F-UMP. Many metabolic pathways are available to F-UMP, including incorporation in to RNA. A reaction sequence crucial for antineoplastic activity involves reduction of the diphosphate nucleotide by the enzyme ribonucleoside diphosphate reductase to the deoxynucleotide level and the eventual formation of 5-fluoro-2'-deoxyuridine-5'-phosphate (F-dUMP). 5-FU also may be converted directly to the deoxyriboside 5-FUdR by the enzyme thymidine phosphorylase and further to F-dUMP, a potent inhibitor of thymidylate synthesis, by thymidine kinase ... The interaction between F-dUMP and the enzyme thymidylate synthase leads to depletion of TTP, a necessary constituent of DNA ... The folate cofactor, 5,10-methylenetetrahydrofolate, and F-dUMP form a covalently bound ternary complex with the enzyme. The inhibitory complex resembles the transition state formed during the normal enzymatic reaction when dUMP is converted to thymidylate. Although the physiological complex progresses to the synthesis of thymidylate by transfer of the methylene group and 2 hydrogen atoms from folate to dUMP, this reaction is blocked in the inhibitory complex by the stability of the fluorine carbon bond on F-dUMP; sustained inhibition of the enzyme results ...
Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill, 2001., p. 1405
Although the precise mechanisms of action of fluorouracil have not been fully elucidated, the main mechanism is thought to be the binding of the deoxyribonucleotide of the drug (FdUMP) and the folate cofactor, N5-10-methylenetetrahydrofolate, to thymidylate synthase (TS) to form a covalently bound ternary complex, which inhibits the formation of thymidylate from uracil, thereby interfering with DNA synthesis. In addition, FUTP can be incorporated into RNA in place of uridine triphosphate (UTP), producing a fraudulent RNA and interfering with RNA processing and protein synthesis.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2007., p. 1048
Fluorouracil is an antimetabolite of the pyrimidine analog type. Fluorouracil is considered to be cell cycle-specific for the S phase of cell division. Activity results from its conversion to an active metabolite in the tissues, and includes inhibition of DNA and RNA synthesis.
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2007., p. 1430
There is evidence that the metabolism of fluorouracil in the anabolic pathway blocks the methylation reaction of deoxyuridylic acid to thymidylic acid. In this manner fluorouracil interferes with the synthesis of deoxyribonucleic acid (DNA) and to a lesser extent inhibits the formation of ribonucleic acid (RNA). Since DNA and RNA are essential for cell division and growth, the effect of fluorouracil may be to create a thymine deficiency which provokes unbalanced growth and death of the cell. The effects of DNA and RNA deprivation are most marked on those cells which grow more rapidly and take up fluorouracil at a more rapid rate. The catabolic metabolism of fluorouracil results in degradation products (eg, CO2 , urea, (alpha)-fluoro-(beta)-alanine) which are inactive. /Efudex Solutions/
Physicians Desk Reference 61st ed, Thomson PDR, Montvale, NJ 2007., p. 3363
For more Mechanism of Action (Complete) data for FLUOROURACIL (7 total), please visit the HSDB record page.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
TAPI offers customized CDMO Solutions for API development and manufacturing services.
GDUFA
DMF Review : Complete
Rev. Date : 2012-11-30
Pay. Date : 2012-11-08
DMF Number : 3062
Submission : 1977-11-09
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4959
Submission : 1983-05-18
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 12738
Submission : 1997-11-11
Status : Active
Type : II
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 1138
Submission : 1968-02-02
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7179
Submission : 1987-10-08
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17832
Submission : 2004-09-08
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6098
Submission : 1985-10-23
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7883
Submission : 1989-01-20
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 2892
Submission : 1977-03-08
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7337
Submission : 1988-02-19
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
Cantargia investigational product CAN04 (nadunolimab), which is an anti-IL1RAP antibody. Currently, it is being evaluated for the treatment of NSCLC.
Lead Product(s): Nadunolimab,Oxaliplatin,Fluorouracil
Therapeutic Area: Oncology Brand Name: CAN04
Study Phase: Phase I/ Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2024
Lead Product(s) : Nadunolimab,Oxaliplatin,Fluorouracil
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Cantargia Reports New Nadunolimab Results in Cancer Clinical Trials
Details : Cantargia investigational product CAN04 (nadunolimab), which is an anti-IL1RAP antibody. Currently, it is being evaluated for the treatment of NSCLC.
Brand Name : CAN04
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 28, 2024
Details:
Cantargia investigational product CAN04 (nadunolimab), which is an anti-IL1RAP antibody. Currently, it is being evaluated for the treatment of NSCLC.
Lead Product(s): Nadunolimab,Oxaliplatin,Fluorouracil
Therapeutic Area: Oncology Brand Name: CAN04
Study Phase: Phase I/ Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2024
Lead Product(s) : Nadunolimab,Oxaliplatin,Fluorouracil
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Cantargia Provides New Data Supporting Nadunolimab Efficacy After PD1-Inhibitor Relapse
Details : Cantargia investigational product CAN04 (nadunolimab), which is an anti-IL1RAP antibody. Currently, it is being evaluated for the treatment of NSCLC.
Brand Name : CAN04
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 08, 2024
Details:
CV6-168 is a first-in-class DNA uracilation agent that selectively targets the enzyme dUTPase. It is being investigated in combination with fluorouracil in cancer patients.
Lead Product(s): CV6-168,Fluorouracil
Therapeutic Area: Oncology Brand Name: CV6-168
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2024
Lead Product(s) : CV6-168,Fluorouracil
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CV6 Therapeutics Doses First Patient in Phase 1a Study of dUTPase Inhibitor CV6-168
Details : CV6-168 is a first-in-class DNA uracilation agent that selectively targets the enzyme dUTPase. It is being investigated in combination with fluorouracil in cancer patients.
Brand Name : CV6-168
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 15, 2024
Details:
Leap intends to use the net proceeds from the financing to fund the continued development of its lead monoclonal antibody program, DKN-01 for the treatment of Colorectal Cancer.
Lead Product(s): Sirexatamab,Fluorouracil,Irinotecan Hydrochloride
Therapeutic Area: Oncology Brand Name: DKN-01
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Gilead Sciences
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 11, 2024
Lead Product(s) : Sirexatamab,Fluorouracil,Irinotecan Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Gilead Sciences
Deal Size : $40.0 million
Deal Type : Private Placement
Leap Therapeutics Announces $40 Million Private Placement
Details : Leap intends to use the net proceeds from the financing to fund the continued development of its lead monoclonal antibody program, DKN-01 for the treatment of Colorectal Cancer.
Brand Name : DKN-01
Molecule Type : Large molecule
Upfront Cash : Undisclosed
April 11, 2024
Details:
Ipsen acquired exclusive commercialization rights for Onivyde, an encapsulated formulation of irinotecan as a first-line treatment for metastatic adenocarcinoma of the pancreas in the US.
Lead Product(s): Irinotecan Hydrochloride,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Brand Name: Onivyde
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Ipsen
Deal Size: $1,025.0 million Upfront Cash: $575.0 million
Deal Type: Acquisition March 27, 2024
Lead Product(s) : Irinotecan Hydrochloride,Fluorouracil,Calcium Folinate
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Ipsen
Deal Size : $1,025.0 million
Deal Type : Acquisition
Merrimack Receives $225 Million Milestone Payment from Ipsen
Details : Ipsen acquired exclusive commercialization rights for Onivyde, an encapsulated formulation of irinotecan as a first-line treatment for metastatic adenocarcinoma of the pancreas in the US.
Brand Name : Onivyde
Molecule Type : Small molecule
Upfront Cash : $575.0 million
March 27, 2024
Details:
AbilityPharma to obtain financing for the clinical development of ABTL0812 in combination with folfirinox. It is being evaluated in Phase I/II clinical trial studies for Metastatic Pancreatic Cancer.
Lead Product(s): ABTL0812,Calcium Folinate,Fluorouracil
Therapeutic Area: Oncology Brand Name: ABTL0812
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: CTI Life Sciences
Deal Size: $7.6 million Upfront Cash: Undisclosed
Deal Type: Financing March 11, 2024
Lead Product(s) : ABTL0812,Calcium Folinate,Fluorouracil
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : CTI Life Sciences
Deal Size : $7.6 million
Deal Type : Financing
AbilityPharma Raises €7M to Advance Phase 2b ABTL0812 for Metastatic Pancreatic Cancer
Details : AbilityPharma to obtain financing for the clinical development of ABTL0812 in combination with folfirinox. It is being evaluated in Phase I/II clinical trial studies for Metastatic Pancreatic Cancer.
Brand Name : ABTL0812
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 11, 2024
Details:
Oncotelic's lead product candidate, OT-101, is a TGF beta-2 inhibitor combined with folfirinox. It is currently under evaluation in Phase 2/3 trials for treating pancreatic ductal adenocarcinoma.
Lead Product(s): OT-101,Calcium Folinate,Fluorouracil
Therapeutic Area: Oncology Brand Name: OT-101
Study Phase: Phase II/ Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2024
Lead Product(s) : OT-101,Calcium Folinate,Fluorouracil
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Invitation to Participate in STOP-PC Clinical Trial
Details : Oncotelic's lead product candidate, OT-101, is a TGF beta-2 inhibitor combined with folfirinox. It is currently under evaluation in Phase 2/3 trials for treating pancreatic ductal adenocarcinoma.
Brand Name : OT-101
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 04, 2024
Details:
Onivyde (irinotecan), liposomal injection is a small molecule drug that blocks an enzyme called topoisomerase I. It is being developed for the treatment of metastatic pancreatic adenocarcinoma.
Lead Product(s): Irinotecan Hydrochloride,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Brand Name: Onivyde
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2024
Lead Product(s) : Irinotecan Hydrochloride,Fluorouracil,Calcium Folinate
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Onivyde Regimen Approved by FDA as First-Line Therapy in Metastatic Pancreatic Cancer
Details : Onivyde (irinotecan), liposomal injection is a small molecule drug that blocks an enzyme called topoisomerase I. It is being developed for the treatment of metastatic pancreatic adenocarcinoma.
Brand Name : Onivyde
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 13, 2024
Details:
AMP945 (narmafotinib) is a novel focal adhesion kinase (FAK) inhibitor. It is being evaluated in precliical studies for the treatment of patients with pancreatic cancer.
Lead Product(s): AMP945,Calcium Folinate,Fluorouracil
Therapeutic Area: Oncology Brand Name: AMP945
Study Phase: IND EnablingProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2024
Lead Product(s) : AMP945,Calcium Folinate,Fluorouracil
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Clearance of Amplia's IND for Pancreatic Cancer Trial in US
Details : AMP945 (narmafotinib) is a novel focal adhesion kinase (FAK) inhibitor. It is being evaluated in precliical studies for the treatment of patients with pancreatic cancer.
Brand Name : AMP945
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 17, 2024
Details:
CV6-168 is a first-in-class DNA uracilation agent that selectively targets the enzyme dUTPase.
Lead Product(s): CV6-168,Fluorouracil
Therapeutic Area: Oncology Brand Name: CV6-168
Study Phase: IND EnablingProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2023
Lead Product(s) : CV6-168,Fluorouracil
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CV6 Therapeutics Receives MHRA Approval for Novel Cancer Therapy Phase 1a Clinical Trial
Details : CV6-168 is a first-in-class DNA uracilation agent that selectively targets the enzyme dUTPase.
Brand Name : CV6-168
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 14, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATES SUPPLIERS
CAS Number : 56177-80-1
End Use API : Fluorouracil
About The Company : Nantong Jinghua Pharmaceutical is a public pharmaceutical company that was established in 1957, owns about 302 staff, located in No. 20, 3 Haibin Road, Yanhai E...
CAS Number : 1480-96-2
End Use API : Fluorouracil
About The Company : Nantong Jinghua Pharmaceutical is a public pharmaceutical company that was established in 1957, owns about 302 staff, located in No. 20, 3 Haibin Road, Yanhai E...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
Regulatory Info :
Registration Country : Australia
Brand Name : TOLAK 4% ONCE DAILY
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info : RX
Registration Country : USA
Brand Name : FLUOROURACIL
Dosage Form : CREAM;TOPICAL
Dosage Strength : 5%
Packaging :
Approval Date : 2008-04-11
Application Number : 77524
Regulatory Info : RX
Registration Country : USA
NanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.
Regulatory Info :
Registration Country : Iran
Brand Name : Fiverna
Dosage Form : Vial
Dosage Strength : 250MG/5ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
NanoAlvand is the entrance to Global Markets as a trusted Highly Potent Products manufacturer.
Regulatory Info :
Registration Country : Iran
Brand Name : Fiverna
Dosage Form : Vial
Dosage Strength : 1000MG/20ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Naprod is a top player in Oncology & Anesthesia FDF through excellent innovation, discovery of new processes & high-quality production.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Liquid Injection
Dosage Strength : 50MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info :
Registration Country : Norway
Brand Name : Tolak
Dosage Form : Cream
Dosage Strength : 40mg/g
Packaging : Tube 20g
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info : RX
Registration Country : USA
Brand Name : FLUOROURACIL
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 5GM/100ML (50MG/ML)
Packaging :
Approval Date : 2023-10-18
Application Number : 217676
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : FLUOROURACIL
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 5GM/100ML (50MG/ML)
Packaging :
Approval Date : 2017-12-26
Application Number : 210124
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : TOLAK
Dosage Form : CREAM;TOPICAL
Dosage Strength : 4%
Packaging :
Approval Date : 2015-09-18
Application Number : 22259
Regulatory Info : RX
Registration Country : USA
Regulatory Info :
Registration Country : Australia
Brand Name : Fluorouracil Ebewe
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
RLD : No
TE Code : AB
Brand Name : FLUOROURACIL
Dosage Form : CREAM;TOPICAL
Dosage Strength : 5%
Approval Date : 2008-04-11
Application Number : 77524
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code :
Brand Name : FLUOROURACIL
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 50MG/ML
Approval Date : 1986-03-21
Application Number : 89152
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : Yes
TE Code :
Brand Name : CARAC
Dosage Form : CREAM;TOPICAL
Dosage Strength : 0.5%
Approval Date : 2000-10-27
Application Number : 20985
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : No
TE Code : AP
Brand Name : FLUOROURACIL
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 2.5GM/50ML (50MG/ML)
Approval Date : 2017-12-26
Application Number : 210124
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code : AP
Brand Name : FLUOROURACIL
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 2.5GM/50ML (50MG/ML)
Approval Date : 2016-02-17
Application Number : 203609
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code :
Brand Name : FLUOROURACIL
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 2.5GM/50ML (50MG/ML)
Approval Date : 2011-05-02
Application Number : 91299
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
Brand Name : FLUOROURACIL
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 5GM/100ML (50MG/ML)
Approval Date : 2011-05-02
Application Number : 91299
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : Yes
TE Code :
Brand Name : FLUOROURACIL
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 500MG/10ML (50MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Approval Date : 1982-01-01
Application Number : 12209
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
RLD : No
TE Code : AT
Brand Name : FLUOROURACIL
Dosage Form : SOLUTION;TOPICAL
Dosage Strength : 5%
Approval Date : 2003-11-05
Application Number : 76526
RX/OTC/DISCN : RX
RLD : No
TE Code : AT
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - SOLUTION;TOPICAL - 2%
USFDA APPLICATION NUMBER - 16831
DOSAGE - SOLUTION;TOPICAL - 5% **Federal Regi...DOSAGE - SOLUTION;TOPICAL - 5% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 16831
DOSAGE - CREAM;TOPICAL - 0.5%
USFDA APPLICATION NUMBER - 20985
DOSAGE - CREAM;TOPICAL - 4%
USFDA APPLICATION NUMBER - 22259
Related Excipient Companies
SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]BioSpectra
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Clariant
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lubrizol Life Science Health
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Bold Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Topical
Solubilizers
Parenteral
Film Formers & Plasticizers
Emulsifying Agents
Coating Systems & Additives
Thickeners and Stabilizers
Fillers, Diluents & Binders
Surfactant & Foaming Agents
Co-Processed Excipients
Direct Compression
Lubricants & Glidants
Controlled & Modified Release
Granulation
Rheology Modifiers
API Stability Enhancers
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
USP
ANALYTICAL
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
